Abstract
The emergence of increasingly antimicrobial-resistant (AMR) Salmonella enterica serovar Typhi (S. Typhi) threatens to undermine effective treatment and control. Here, aiming to investigate the temporal and geographic patterns of emergence and spread of AMR S. Typhi, we sequenced 3,489 S. Typhi isolated from prospective surveillance in South Asia and combined these with a global collection of 4,169 S. Typhi genomes. Our analysis revealed that independent acquisition of plasmids and homoplastic mutations conferring AMR have occurred repeatedly in multiple lineages of S. Typhi, predominantly arising in South Asia. We found evidence of frequent international and intercontinental transfers of AMR S. Typhi, followed by rapid expansion and replacement of antimicrobial-susceptible clades.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a grant from the Bill and Melinda Gates Foundation (grant number INV-008335).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the parent studies were obtained from the Bangladesh Institute of Child Health Ethical Review Committee, Christian Medical College Institutional Review Board, Nepal Health Research Council, Aga Khan University Hospital Ethics Committee and Pakistan National Ethics Committee, Stanford University Institutional Review Board, and U.S. Centers for Disease Control and Prevention. Informed written consent and clinical information were taken from adult participants and legal guardians of child participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Illumina sequence data was submitted to the European Nucleotide Archive. Sequence data from 4,169 S. Typhi strains from previous studies were also included for global context raw sequence data for these isolates are available in European Nucleotide Archive. Details and individual accession numbers of sequence data included in our analysis have been included in Tables S1 and S2.
